# Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia

> **NCT06882031** · PHASE1 · COMPLETED · sponsor: **SDK Therapeutics, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Acute Promyelocytic Leukemia (APL)

## Interventions

- **DRUG:** Treatment A: Arsenic Trioxide (ATO) Intravenous
- **DRUG:** Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state
- **DRUG:** Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state
- **DRUG:** Treatment D: SDK001 (Arsenic Trioxide Oral solution) with calcium carbonate

## Key facts

- **NCT ID:** NCT06882031
- **Lead sponsor:** SDK Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-11
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-06-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06882031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06882031, "Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06882031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*